

Clinical classification in mental health at the cross-roads: which direction next?

Ian Hickie, Jan Scott, Daniel Hermens, Elizabeth Scott, Sharon Naismith,
Adam Guastella, Nick Glozier, Patrick McGorry

► **To cite this version:**

Ian Hickie, Jan Scott, Daniel Hermens, Elizabeth Scott, Sharon Naismith, et al.. Clinical classification in mental health at the cross-roads: which direction next?. BMC Medicine, BioMed Central, 2013, 11 (1), pp.125. <10.1186/1741-7015-11-125>. <inserm-00823373>

HAL Id: inserm-00823373

<http://www.hal.inserm.fr/inserm-00823373>

Submitted on 16 May 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

DEBATE

Open Access

Clinical classification in mental health at the cross-roads: which direction next?

Ian B Hickie^{1*}, Jan Scott^{2,3,4}, Daniel F Hermens¹, Elizabeth M Scott^{1,5}, Sharon L Naismith¹, Adam J Guastella¹, Nick Glozier¹ and Patrick D McGorry^{6,7}

Abstract

Background: After 30 years of consensus-derived diagnostic categories in mental health, it is time to head in new directions. Those categories placed great emphasis on enhanced reliability and the capacity to identify them via standardized checklists. Although this enhanced epidemiology and health services planning, it failed to link broad diagnostic groupings to underlying pathophysiology or specific treatment response.

Discussion: It is time to adopt new goals that prioritize the validation of clinical entities and foster alternative strategies to support those goals. The value of new dimensions (notably clinical staging), that are both clinically relevant and directly related to emerging developmental and neurobiological research, is proposed. A strong emphasis on 'reverse translation' (that is, working back from the clinic to the laboratory) underpins these novel approaches. However, it relies on using diagnostic groupings that already have strong evidence of links to specific risk factors or patterns of treatment response.

Summary: The strategies described abandon the historical divides between clinical neurology, psychiatry and psychology and adopt the promotion of pathways to illness models.

Keywords: Classification, Clinical staging, Mental health

Background

Globally, the biggest challenge in public mental health is implementing strategies to reduce the societal burden of mental disorders [1,2]. For those living with mental illness and their families, the most pressing issues are increasing access to affordable health care, promoting social inclusion, supporting economic productivity and reducing premature mortality [1-4]. From a clinical perspective, our greatest failure has been the lack of development of new or better-targeted treatments, particularly for those with persisting and disabling disorders. Additionally, our inability to predict individual responses to treatments and our failure to intervene early to reduce disability or prevent premature death are notable [5-10].

Despite the degree of public or media attention [11-13], deciding the immediate fate of our major international classification systems is not our most central task. It is timely, however, to reflect on the Diagnostic and Statistical Manual

(DSM) for Mental Disorders, fourth edition [14] and the closely related International Classification of Diseases, 10th revision (ICD-10) [15]. The application of these systems has improved the reliability of syndromal (symptom-based) diagnoses as used in psychiatry, but these remain inferior to the evidence-based etiological or pathway models employed for other common medical conditions.

After 30 years of clinical research, which is based on a common set of principles, our diagnostic entities remain poorly validated. That is, despite the research explosion in basic neuroscience, imaging and molecular genetics, our categories do not link strongly to any specific neurobiological or environmental risk factors, underlying pathophysiological processes, or patterns of specific treatment response [5,6,16-18]. Consequently, our classification systems have arrived at a fundamental cross-road.

While the DSM processes seem set to continue down familiar paths [19], it is timely to consider whether clinical psychiatry and psychology would be better served by heading in somewhat different directions [20-26]. Here, we explore specific alternatives including a much greater fusion of classification systems with other areas

* Correspondence: ian.hickie@sydney.edu.au

¹Clinical Research Unit, Brain & Mind Research Institute, University of Sydney, 100 Mallett Street, Camperdown 2050, Australia

Full list of author information is available at the end of the article

of clinical neuroscience, the use of dimensional measures of behavioral and cognitive change, the adoption of a limited number of pathophysiologically based syndromes that incorporate objective testing, a greater reliance on implications of response to specific treatments, and the extent to which incorporation of a common general medical concept - namely, clinical staging - represents a major advance [27,28]. Most importantly, we suggest that such alternatives take us a much greater way along the path to enhanced treatment planning.

The clinical challenge

It is frustrating that diagnoses are based largely on descriptive phenomena. Often they vary from practitioner to practitioner, and may well change markedly over the course of illness (for example, non-psychotic to psychotic syndrome or unipolar to bipolar mood disorder). As diagnoses are made at non-specific time points along complex illness pathways that evolve from risk to onset and progression to chronic ill-health, they often relate poorly to the actual stage of illness. For the major anxiety, mood or psychotic disorders, the illness process typically has its onset in late childhood or early puberty and then recurs or continues progressively into adult life [29-31]. Although 75% of major mental disorders begin before the age of 25 years [32], our diagnostic criteria are derived largely from the experiences reported by middle-aged persons with established illness. These phenotypes often map poorly onto earlier and often less specific phases of the illness experience [22,25,33,34].

The current systems also assume the concept of multiple parallel pathways each leading to distinct diagnostic categories - an assumption that is not readily supported by modern family, genetic and neurobiological risk factor studies [20,35,36]. Criterion-based symptom sets (which then give rise to specific and 'independent' categories) prioritize phenomena such as delusions, hallucinations, periods of elevated mood or increased energy, psychomotor slowing, emotional blunting, or cognitive slowing for disorders such as schizophrenia, bipolar disorder or severe depression. Data from recent community studies that assess patients longitudinally from childhood or adolescence [29,37-39], however, emphasize the extent to which many of these phenomena are shared across disorders [40]. Prototypically, anxiety disorders that are evident in children before the age of 12 years predict later depressive, bipolar and psychotic disorders [41].

With regards to adult-type disorders, persistence or recurrence of symptoms appears to have greater predictive significance than cross-sectional observation of specific symptoms [39,42-45]. Hence, the great clinical challenge is to derive new diagnostic systems that are not only consistent with developmental epidemiology and neurobiology but also useful when applied in everyday clinical practice.

A historical perspective

The great virtue of the research-based classification systems of the late 1970s was that they promoted the pursuit of reliable diagnoses. To achieve diagnostic reliability, a small number of dimensions in human behavior (for example, anxiety, depression, impaired cognition or psychotic phenomena) were organized into a large number of discrete and separate 'disorders' - on the basis of the presence or absence of set numbers of key symptoms. Inevitably, this gave rise to a checklist approach to diagnostic practice and the proliferation of diagnostic 'categories'.

However, reliability was oversold as the necessary precursor to validation of those entities [16]. While the 'atheoretical' and reliability-driven approach of DSM-III did set clinical research free from the previous psychological, behavioral or medical models, it did not result in a new era of preventive and therapeutic strategies. In retrospect, it appears that the DSM-III-derived disorders or independent categories relied too heavily on descriptive psychopathology, historical practice or clinical consensus [46,47].

The post-DSM-III era did enhance our capacity to conduct large, multi-site and international research and ensured that diagnostic concepts were less constrained by local history, culture, religion or social customs, or fashion. Such aspirations were essential to promoting the international 'science' base of clinical psychiatry and psychology and for forging links to key areas of emerging neuroscience, especially molecular genetics and neuroimaging. Further, this greatly assisted the move away from highly idiosyncratic practice or 'diagnostic systems' that were used to prop up the delivery of poorly evaluated (or intrinsically harmful or discriminatory) forms of mental health care. Mental health practice is one area of social endeavor that has benefited greatly from globalization and greater transparency, communication and scrutiny [2].

When linked to national epidemiological surveys, the international classification systems have underpinned more accurate estimates of relative disease burden, access to care and impacts of mental disorders on broader health and social systems [1,32,48]. This has led to more forward thinking about how to best support broad social settings that enhance mental health and wellbeing [49]. Thus, in many ways, the great successes of the post-DSM-III diagnostic era are in public health and related health system developments. It is rather frustrating that, despite the best efforts of scientists and practitioners, the stated aims of advancing clinical research have not been so successful.

Discussion

Setting new goals for international classification systems

Given the relative failure to validate the DSM- or ICD-derived categories, it is time to set new goals (Table 1) -

Table 1 New goals for enhanced diagnostic categories and worked examples for major depression

Clear goals	Consequences for diagnoses related to major depression
1. Focus primarily on enhancing clinical practice	<p>1. Abandon use of the single term 'major depression' as on its own it does not predict response to specific psychological or physical treatments [62];</p> <p>2. Only use in association with specifiers that predict likely response to specific treatments - for example, major depression with psychotic features; melancholia associated with psychomotor changes [63-65]; depression following manic episode [62];</p> <p>3. Differentiate other risk or comorbidity factors from the diagnosis itself - notably risk of self-harm or suicide or misuse of alcohol and other substances [66-69].</p>
2. Link directly to objective markers of pathophysiological processes	<p>Require the cross-sectional and longitudinal recording of objective markers that may predict response to treatment or risk of recurrence:</p> <ul style="list-style-type: none"> • Neurohormonal - for example, presence of non-suppression to dexamethasone [70]; • Circadian or sleep - for example, actigraphic evidence of phase-delay [58,60,71]; • Psychomotor change - for example, observer or automated measures [63-65]; • Neuropsychological - for example, neuropsychological evidence of delayed reaction time [72-75]; • Brain imaging - for example, presence of subcortical white matter changes [59,74,76-82].
3. Incorporate known facts about developmental paths, environmental risk factors, course of illness or family history	<p>1. Differentiate early-onset (<30 years) from late-onset (>50 years) forms [83-87];</p> <p>2. Differentiate first major episode from recurrence, relapse or chronicity [21,22,52,88];</p> <p>3. Record clear environmental (for example, seasonal onset, exposure to traumatic events) or medical illness (for example, post-stroke) exposures that are concurrent with depression [89];</p> <p>4. Record clear earlier (notably childhood) phenotypes such as childhood anxiety;</p> <p>5. Record clear family history data related to presence of psychosis, mania or suicide in first-degree relatives [35,37,90-95];</p> <p>6. Record clear history of exposure to social adversity or interpersonal stressors or ongoing evidence of major socio-economic, interpersonal or other relevant social circumstances [96-98].</p>
4. Be consistent with data from family, twin or genetic studies	<p>1. Restrict the diagnosis to those sub-categories with strong evidence of high heritability - for example, depression in those with previous mania; depression in those with psychotic features [35,37,38,99-101];</p> <p>2. Support the concepts of depressive disorders preceded by childhood anxiety or early-versus late-onset depressive disorders [66,84-86,102].</p>
5. Capture key aspects of illness stage	<p>Use a clinical staging format for depressive disorders that differentiates early stages that are strongly linked to other childhood and adolescent phenotypes (for example, anxiety, phase-delay in sleep and circadian systems, fatigue, hypomania, mood instability) from later early adult or mid-adult stages (which may also be associated with different phenotypes such as psychomotor change, phase-advance in sleep and circadian systems) [21,22,58-61,88,102].</p>
6. Best predict future illness course or response to specific treatments.	<p>Use known factors about response/non-response to specific treatments - for example, for acute episode: classify as selective serotonin reuptake inhibitor responder or non-responder; classify as responder or non-responder to cognitive behavioral therapy [103-105].</p>

and propose a range of possible, and rather diverse, strategies to support those goals (Table 2). An overriding concern in mental health has become the reduction of the population-health burden by adoption of various early intervention strategies [28,50,51]. These focus clinical service development and related research on identifying early forms of illness not only to reduce current morbidity but also to prevent progression to more severe or chronic illness types and associated role impairment [52-57]. Although the fundamental empirical work in this area has focused largely on psychotic disorders, there is now a much broader clinical database emerging that is targeted at the early phases of the more prevalent anxiety and depressive disorders [22,53,58-61].

This movement is similar in conceptualization with that being promoted in other related clinical areas of medicine that have very large impacts on current and future health costs, notably diabetes and related metabolic syndromes [125-127]. As with the move to define pre-diabetes (an intermediate state between normal and clearly raised blood glucose concentrations), it is entirely possible to define emerging mental disorders by their intermediate symptom levels, impacts on function, patterns of persistence over time or predictive capacity [21,22,56,57]. Further, it is possible to design new health care platforms to increase the access to care for young people presenting with these conditions [53,55].

Importantly, the same types of concerns arise in the arenas for both pre-diabetes and early intervention in

Table 2 New strategies for deriving diagnostic categories and worked examples for major depression

New strategies	Implications for major depression
1. Abandon the artificial distinction between brain (neurological) and psychiatric or psychological (mental) disorders	1. Focus clinical attention on the broad affective, cognitive, motor and sleep or circadian aspects of significant depressive disorders [58-61,72,106]; 2. Encourage systematic cross-sectional and longitudinal structural brain imaging across the various phases of early- and late-onset depressive disorders [78,83].
2. Avoid the use of single categorical states (for example, major depression, schizophrenia, bipolar disorder) that describe heterogeneous groups	Only use major depression in association with specific descriptors including early- versus late-onset, preceded by childhood anxiety; comorbid with alcohol or other substance misuse, significant circadian disturbance, psychotic features, significant psychomotor disturbance or other discrete melancholic features [61,63-65,78,84,107-110].
3. Promote pathways to illness models that have a strong basis in longitudinal epidemiology and related risk factor or neuroscience research	Promote categories such as depression preceded by childhood anxiety; childhood traumatic events; depression associated with significant circadian disturbance; depression associated with psychomotor change; depression following a clear manic episode [61].
4. Incorporate age-of-onset and stage-of-illness concepts into all diagnostic processes	1. For depression, the first age of a clear depressive syndrome would be recorded, as well as the first clear episode of sufficient severity to justify intervention [66,111,112]; 2. For depression, the clear pattern of remission, relapse or recovery would be recorded for all patients [113].
5. Reduce the concept of comorbidity to the co-occurrence of genuinely independent conditions	1. Depression occurring in association with documented diabetes or cardiovascular disease [114-119]; 2. Rejecting the notion of anxiety and depression representing comorbid conditions, as distinct from linked developmental phenotypes [61].
6. Place greater importance on the significance of response to specific treatments	1. Patients with anxiety and depression who fail to respond in the acute phase to CBT but do respond to an SSRI or SNRI can be considered to be in a different category [103,104,113]; 2. Patients with psychomotor change or cognitive impairment who do not respond to SSRI or SNRI but do respond to physical treatments such as electroconvulsive therapy can be considered as a different category [64,120]; 3. Patients with sleep or circadian disturbance who fail to respond to respond to CBT or SSRI or SNRI but do respond to behavioral or pharmacological management that targets the circadian system can be considered to be in a different category [121-124].

CBT: cognitive behavioral therapy; SNRI: selective norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor.

mental health [51,128]. That is, as the number of individuals identified by health systems grows, and those with less severe forms come into active clinical care, the extent to which early forms of illness can be effectively managed largely by non-pharmacological or other lifestyle-based approaches is a key consideration [66,129,130]. Critics of this area [11,131] all too readily see an over-medicalization or a pharmaceutical-industry-driven conspiracy to be at the heart of such genuine public health movements. Yet the evidence from the clinical staging of ischemic heart disease largely demonstrates the opposite. The greatest public health emphasis was placed on reducing smoking rates, promoting exercise and addressing other modifiable risks. High cost, high risk interventions (for example, revascularization) were reserved for those experiencing major events (for example, first myocardial infarct), those with recurring episodes (for example, coronary by-pass surgery), or following a progression to chronic disease (for example, pharmacotherapy of heart failure) [132,133].

Currently, the key difference between the diabetes and early mental disorder arenas is the extent to which the diagnosis of the 'at-risk' or 'prodromal' state for diabetes relies on an independent laboratory test - and the extent to which that laboratory test has predictive value for

later poor health outcomes. Therefore, concurrently with the development and evaluation of earlier diagnostic thresholds based on descriptive phenomena and related disability estimates [22,52,53], we must intensify our search for better neuropsychological, brain imaging, circadian, neurophysiological, immune or other markers of these early states [58,59,72,76,99,106,134-136] and design studies to test their predictive capacity.

These new goals respond directly to the challenges posed by novel preventive and longitudinal approaches that are targeted at the recognition of early phenotypes. For example, for depressive disorders, there is international recognition that the extraordinary premature death and disability costs attributable to these conditions [48,137] reflect their early age-of-onset, high current and lifetime population prevalence, typical illness patterns of recurrence and chronicity, and likely comorbidity with alcohol and other substance misuse as well as physical ill-health, most notably in the form of premature cardiovascular disease [90,107,138-141]. The ways in which incorporating these new goals might impact on the classification of depressive disorders is outlined here (see Table 1).

As importantly, it is necessary to state those factors which are not the primary goals of a clinical or research

classification system. These include: categorizing all forms of abnormal perception, mood, cognition or other behavioral disturbance; imposing independent category status on disturbances that are fundamentally dimensional in nature and frequently inter-correlated (see common forms of anxiety and depression [142,143]); creating diagnostic hierarchies that presume etiological or pathophysiological dominance of one form of disturbance over another (for example, psychotic compared with mood or cognitive phenomena); or using the classification system as the sole basis for allocating research funds, licensing treatments, providing access to health care, determining legal matters, reimbursing health care costs or supporting access to other personal entitlements system.

Contrary to prevailing wisdom, there is no urgent need to have one over-arching international diagnostic system or bible for all perceptual, mood, cognitive and other behavioral syndromes. Unfortunately, the recent attempts to include all things within the one descriptive system have underpinned a rather unhelpful debate about the inclusion or exclusion of fewer or more categories [11,12,144]. Another unintended side-effect of the forced international orthodoxy was the lack of support of other plausible models or active support for the development of alternative approaches [13,16,145].

An emerging body of work, utilizing appropriate genetic modeling and brain imaging data provides provisional support for such alternative approaches [20]. These data favor a model in which mental disorders represent broad patterns of psychopathology. Within this model, various genetic and environmental factors determine the development of common brain circuits that underpin normal behavior and cognition. When perturbed, changes in the function of these circuits give rise to deviant behavior or cognitive function. This model has influenced the National Institutes of Mental Health, which now actively promotes investigation of brain-circuit-based approaches and proposes that they may underpin a new approach to the classification of common mental disorders [20,146].

Within the circuitry models, changes from normal function (thereby giving rise to disorders) are by their nature dimensional rather than categorical. Generally, correlations exist between the degree of accumulated dysfunction of the underlying circuits (or related systems) and the extent of behavioral or cognitive change. This dimensional approach shifts the emphasis from making a specific diagnosis to determining the current level of cognitive or behavioral change in individual patients. Clinical and related neurobiological research then examines the extent to which common risk variables (for example, developmental delay, trait neurocognitive impairments, alcohol or other substance misuse) increase risk to measured behavioral or cognitive change, increase risk to markers of brain impairment (for example, poor neuropsychological function,

excessive cortical thinning, disturbed neurophysiological markers) or increase risk to poor outcomes - independently of any specific relationship with classical 'diagnostic' entities [108,147,148].

Core dimensions of cognition and behavior are hypothesized to be common to all persons and not viewed as a unique set of characteristics occurring only in those who present with mental health problems. Perturbations of brain circuits will typically result in 'trans-diagnostic' rather than pathognomonic symptom sets. An important prediction of such systems is that many objective measures of the structure (for example, brain imaging) or outputs of such systems (for example, cognition - including traditional neuropsychological and social cognition, circadian, hypothalamus-pituitary-adrenal axis function, neurophysiological or immune) will also show little diagnostic specificity. Over the last 30 years, this has been the overwhelming experience with proposed diagnostic markers, such as the dexamethasone suppression test for major depression [149]. Preliminary analyses of data from those in the early phases of a range of major psychotic or mood disorders also support this perspective [58-61,72,73,76,99,106,136,150,151].

New strategies for enhancing the diagnoses of perceptual, mood, cognitive and other behavioral syndromes

A range of diverse strategies can be advanced to support these new goals (see Table 2). These do not need to come together into one single bible for clinical or research purposes, as the initial aim is to develop, evaluate and refine them frequently as evidence emerges. A potential consequence of the key shift from many categories to the use of fewer underlying dimensions is that it is likely to lead to the need for an alternative term to mental disorders. A very broad descriptive concept that encapsulates a 21st century approach to disturbances of perception, mood, cognition and other behavioral dimensions may be required. The clear public, professional, clinical and research benefits likely to derive from abandoning the historical and cultural divisions between clinical neurology and psychiatry and clinical psychology have been highlighted by others [13,26].

In doing so, such strategies move away from the very broad categories we currently use (for example, major depression) to describe very heterogeneous populations. Generally, more specific states (for example, depression in association with late-life vascular disease; first episode psychosis; cannabis-associated recurrence of psychosis; depressive episode following previous manic episode) provide a better fit with known risk factors, actual pathophysiology or known illness course and may be much more useful in research and some fields of clinical practice [83].

In association with all disorders, more general age-of-onset and stage-of-illness concepts should be recorded. Those that have clear pathways to illness need to be emphasized (for example, childhood attention deficit hyperactivity disorder leading to early age of onset of substance misuse; childhood schizotypal or autistic behaviors leading to early onset psychotic disorder; adolescent social anxiety leading to alcohol misuse). Concurrently, this may help to reduce the overuse of the concept of comorbidity - limiting it in the future to the co-occurrence of genuinely independent conditions (for example, psychotic disorder and alcohol dependence).

It is clear that one of the most robust ways of differentiating diagnostic groups is on the basis of response (or non-response) to specific treatments. Much greater effort needs to be invested in the reverse translation agenda (that is, working back from the bedside to the bench). For example, we urgently need to unravel what neurobiological factors differentiate those with schizophrenia who respond to clozapine or those with bipolar disorder who respond to lithium. The goal is to develop better predictors of treatment-response before initiating therapies.

At this time, we argue that we may be better served by investing heavily in a much smaller number of more discrete syndromes that are partially validated by clinical course, objective markers or predictors of treatment response. That is, rather than prioritize reliability, we could vigorously pursue those more homogeneous groups that are identified in clinical practice or family studies [90-93]. Inevitably, this would advance the push for more personalized approaches to health care. Further, relevant groups could be preferentially recruited to specific preventive or treatment trials (for example, late-onset depression; childhood-onset obsessive-compulsive disorder; psychotic disorder preceded by childhood schizotypal behaviors; first-episode mania; depressive disorders characterized by disturbed hypothalamic-pituitary function, circadian disruption or immune activation).

Another clear way of approaching this desire for greater specificity is to focus on syndromes that are closely linked with discrete environmental exposures, social adversity or inter-current medical events [152]. These natural experiments can be used to facilitate more targeted pathophysiological studies (for example, post-infective or post-stroke neuropsychiatric syndromes; post-traumatic depressive states; depression or prolonged fatigue states following cancer therapies; alcohol or other substance misuse neuropsychiatric syndromes; cannabis-associated first episode of psychosis [89,153-156]).

We would also promote an overt move away from checklist-driven criteria that rely on poorly validated symptom sets (for example, treating independent symptoms such as sleep disturbance and suicidal ideation as equivalent items for the diagnosis of major depressive


disorders). Instead, we favor a move back towards clear syndromes that share key pathophysiological, symptom or illness course features (for example, psychotic depression; melancholic disorders that are associated with concurrent psychomotor change; first-episode psychosis; bipolar disorder diagnosed by a discrete manic episode). This process would also be assisted by greater use of objective markers of key features of disorders (for example, computer-generated measures of neurocognitive function; actigraphy-generated measures of sleep-wake cycle; self-report based measures of cognitive styles) and wider use of clinician or self-reported measures of key symptom dimensions.

Promoting the use of clinical staging

One of the most important developments in recent years has been the importing of the concept of clinical staging from general medicine. In other clinical domains (for example, oncology, coronary heart disease, inflammatory joint disease), it is totally inadequate to choose treatments, or plan health care, for persons who suffer from recurring or progressive conditions simply on the basis of a broad diagnostic category (for example, breast cancer). We suggest that it is equally meaningless in mental health to select specific treatments on the basis of broad categories such as schizophrenia, bipolar disorder or major depression. There is a wealth of evidence indicating that patients at different points along the illness continuum of all of these conditions show quite different patterns of response to various interventions [21,88,157,158].

Consequently, we have proposed a general framework for clinical staging that can be applied to the more severe mood or psychotic disorders (Figure 1). This framework is readily applied to those who present for health care and clearly differentiates those in early phases (stages 1a 'seeking help' or 1b 'attenuated syndromes') from those who have reached a higher threshold for disorder (stage 2 and above - see Figure 1). Current clinical and related neurobiological studies (for example, magnetic resonance imaging; neuropsychological and sleep/circadian studies) of this framework provide provisional evidence in support of its reliability and validity [22,58,59].

As compared with current DSM and ICD disorder thresholds, and particularly for the common anxiety and depressive disorders, this approach raises the bar for the initiation of more specific or intensive pharmacological or behavioral strategies. That is, although this approach does encourage more active health care for those at lower levels of illness, it also promotes the use of safe, easily-delivered and non-specific psychological intervention, health-care, suicide prevention and other secondary prevention strategies for those who have not yet reached the higher threshold for a stage 2 disorder [54,84].



Likely benefits of developing multiple diagnostic dimensions and linking these to clinical staging

All of these strategies move the emphasis from the rather sterile academic debates about the virtues of competing symptom sets (or illness thresholds) [159-161] to the provision of relevant treatment at key points along an illness path. In dialogue with individual patients, this would result in the provision of far more accurate, multi-dimensional and context-relevant information. In our view, stating clearly that a 21-year-old man has a first-onset psychosis, with a strong family history of mania and associated five-year history of persistent cannabis use is more likely to guide treatment selection, health care planning and accurate prognostic statements than assigning any of the current psychosis disorder categories. Similarly, stating that a 17-year-old girl has the recent onset of a depressive disorder characterized by psychomotor slowing and preceded by prolonged fatigue, seasonal changes in mood and energy, with no evidence of childhood anxiety or concurrent alcohol or substance misuse is more useful than attaching any of the current depression categories. While these approaches are already common in everyday clinical practice they are not captured in our current diagnostic systems.

Further, we need systems that support innovative research paradigms such as those promoted by the youth mental health for common mental disorders and early intervention in psychosis movements [162,163]. Within these novel paradigms, it is far more important to recruit patients who share key demographic, illness stage, prior treatment characteristics or family history (for example, age, gender, duration of illness, lack of prior

exposure to medical treatments, family history of psychosis or mania) rather than pre-selecting on the basis of poorly-validated syndromal constructs such as major depression.

Such novel research paradigms inevitably focus attention on those genetic or environmental risk factors that are common across disorders (and hence may be modified with resulting benefits to a large number of persons), distinct from the narrow search for unique risk factors that link specifically to each separate disorder. Key considerations such as the role of intra-uterine environments, early childhood infections, childhood sexual or emotional abuse, early adolescent alcohol or substance misuse, grossly distorted adolescent sleep patterns, and physical inactivity in the teenage years will then emerge as major foci for targeted research and potential public health programs [58,60,108,164-166].

Implications for clinical research and reverse translation

These alternative approaches to classification would give rise to a new wave of early intervention, biomarker, clinical intervention and other longitudinal studies. Specifically, they would also promote reverse translation initiatives - meaning those research programs that work back from clinical research based on well-characterized, more narrow and probably more homogeneous patient groups to elucidate more fundamental biological correlates. Additionally, the reverse translation agenda has other important attributes, including actively responding to topics of real significance to those living with the illness (for example, cognitive impairment in those with psychotic disorders) and capitalizing on phenomena that have been well-replicated in

Table 3 Reverse translation research agenda for circadian-based mood disorders

Reverse translation strategies	Specific research studies
1. Identify cohorts with clear indicators of circadian-based pathophysiology [58,60,99,167,168]	<p>1. Establish relevant clinical cohorts. For example:</p> <p>a. early-onset depression with family history of mania;</p> <p>b. less than 10 years of active illness with lithium-responsive mania;</p> <p>c. early-onset depression with evidence seasonal change in disorder severity or preferential response to behavioral or pharmacological circadian-based interventions;</p> <p>2. Introduce circadian-based phenotypes or markers to other relevant epidemiological, clinical or longitudinal studies. For example:</p> <p>a. sleep-wake cycle and circadian phenotypes into relevant developmental, family, genetic or twin studies;</p> <p>b. sleep-wake cycle and circadian phenotypes into relevant population-based studies of illness-onset or course.</p>
2. Introduce specific biomarker strategies to the study of cohorts with circadian-based pathophysiology	<p>Introduce objective markers of 24 sleep-wake and circadian activity cycle to descriptive, longitudinal and interventional studies. For example:</p> <p>a. use of smart-phone technologies to track sleep cycles;</p> <p>b. use of ecological monitoring application technologies to study behavioral rhythm patterns;</p> <p>c. use of actigraphy to study timing and stability of activity cycles;</p> <p>d. use of dim-light melatonin assays to study patterns of melatonin onset.</p>
3. Design prevention or clinical intervention studies that are relevant to cohorts characterized by circadian-based dysfunction (for example [104,123,125,169-175])	<p>Trial designs include:</p> <p>a. selection of young patients with depressive disorders and concurrent phase-delay syndromes for evaluation of efficacy of circadian-based behavioral interventions, light therapy, melatonin or agomelatine, remelton or tasimelteon;</p> <p>b. selection of young patients with depression and phase-delay, and family history of mania or psychosis or family history of response to lithium, for evaluation of behavioral or pharmacological strategies to prevent first episode of mania;</p> <p>c. evaluating whether those with bipolar disorder who are most responsive to lithium also have depressive disorders that are preferentially responsive to light therapy, melatonin or agomelatine;</p> <p>d. evaluating the effects of circadian-based interventions on the course of metabolic parameters in young persons treated for depression or bipolar disorder.</p>
4. Initiate specific genetic or pathophysiological studies in those with specific circadian-parameters [176,177]	<p>Examples include:</p> <p>a. specific genetic association for circadian markers in those cohorts who are responsive to lithium or other circadian-specific interventions;</p> <p>b. specific genetic association for circadian markers in family members of those with lithium-responsive bipolar disorder;</p> <p>c. specific genetic association for circadian markers in family members of those with depression who are responsive to light therapy, melatonin or agomelatine;</p> <p>d. evaluate the capacity of cross-sectional and longitudinal dim-light melatonin onset assays to predict the response to treatment or rate of recurrence in those with circadian-based depressive disorders;</p> <p>e. evaluate the capacity of cross-sectional and longitudinal dim-light melatonin onset assays to predict the response to treatment or rate of recurrence in those with bipolar disorders.</p>
5. Designing relevant animal model systems to evaluate the likely therapeutic effect of novel behavioral or pharmacological interventions or better understand the effects of effective interventions on the circadian clock [122,178-180]	<p>1. Development of Zebra fish based assays of effects of differing pharmacologies on circadian-dependent locomotor function in fish larvae;</p> <p>2. Design studies using effective circadian therapies for mood disorders (as defined by human response) in genetically-informative mice to study changes in underlying mechanisms of the circadian clock and its output systems;</p> <p>3. Test novel pharmacological strategies (that is, agents which target molecular mechanisms of the circadian clock) in animal models of depression.</p>

Table 3 Reverse translation research agenda for circadian-based mood disorders (Continued)

6. Development of novel biomarkers of the circadian system for use in risk factor and treatment systems (for example, [181-185])	1. Optimization of measurements of circadian disruption in humans with major affective disorders, via new systems and technologies (for example, circadian phase in fibroblasts) - with a focus on easy repeatable measures not only of phase-shifts but also internal desynchrony;
	2. Relating measures of disruption of the circadian systems to other measures of chronic distress (for example, hair cortisol measures).

studies on humans (for example, lithium-responsive bipolar disorder or clozapine-responsive schizophrenia).

The combination of key clinical insights and patient priorities plays a crucial role in setting the reverse translation research agenda [2]. Categories deserving of detailed neurobiological research are those clinical situations in which a robust link with relevant pathophysiological, risk, illness-stage or treatment variables has already been demonstrated (for example, circadian-based depressive disorders - see Table 3; cannabis-associated psychosis; first-episode mania; or clozapine-responsive schizophrenia disorders).

On the basis of making new links in these smaller but clinically-defined cohorts with the best available markers of the active pathophysiology, we would then expect new insights that could provide a basis for working forwards again (that is, bench back to bedside). A new wave of more relevant animal models, molecular targeting or other rapid assay modalities could emerge. The goal then is to use that new knowledge to implement better targeted and more individualized prevention or active treatment strategies (that is, traditional forward translation programs [167,186-188]). Such translational research programs (that is, those that incorporate both reverse and forward strategies) would then genuinely link 21st century neurobiology to clinical practice in an iterative and mutually-informative discourse.

The impact of the move away from investigating traditional schizophrenia to more focused first-episode psychosis (and then related prodromal or at-risk clinical research) in Australia, Europe and the United Kingdom demonstrates the extent to which these novel approaches can genuinely transform clinical practice [27,56,163]. By contrast, those working in the anxiety and mood disorders fields have been slow to comprehend the significance of these developments [28,85]. We believe the time is now right for a more general shift in direction in favor of those diagnostic practices that focus attention on key developmental, illness course, reverse translation and strategic intervention approaches. Although we can recognize the genuine progress that the DSM and ICD revisions from 1980 onwards supported, there is now no longer any good reason for the international mental health community to be constrained by the ongoing revisions of these systems.

Summary

After 30 years of consensus-based diagnostic categories in mental health, there is great clinical and public frustration with our relative failure to deliver real clinical advances. The approach introduced by the DSM-III (1980) prioritized reliability and imposed a categorical approach on many underlying dimensions of abnormal cognition, mood or behavior. It also sought to 'cover the field' and in doing so gave rise to new entities for further research and evaluation. The general approach enhanced epidemiology, international collaboration and health services planning, but too little progress has been made with linking the multiple broad entities to clear genetic or environmental risk factors, underlying pathophysiology or specific patterns of treatment response. Consequently, we have argued that it is time to prioritize the validation of more robust clinical entities and foster the development of specific strategies to support this priority. The proposed goals put enhanced clinical practice back at the center of the endeavor, work with strong cross-sectional and longitudinal epidemiological, family and twin studies, and use available objective markers. The value of implementing new dimensions, notably clinical staging, that are both clinically relevant and directly related to emerging epidemiological, developmental and neurobiological research is also proposed. The strategies described abandon the historical and cultural divides between clinical neurology, psychiatry and psychology and actively move away from broad descriptive terms (for example, major depression, schizophrenia, bipolar disorder) to the promotion of pathways to illness models. These models incorporate age-of-onset, known environmental risk factors and patterns of response to specific treatments (for example, lithium-responsive bipolar disorder, clozapine-responsive psychosis). A strong emphasis on a reverse translation agenda (that is, working back from the clinic to the laboratory) is highlighted. This agenda relies on using diagnostic groupings that already have strong evidence of links to specific risk factors or patterns of treatment response. We have detailed the ways in which these approaches could enhance clinical practice in the most impactful of the major mental disorders, namely major depression. In this worked example, the term major depression would largely be replaced by much more specific terms that differentiate early- from late-onset, those presentations that fundamentally followed-on from

childhood anxiety and those disorders that were strongly linked with objective measures of circadian disturbance. As with all other disorders, clinical staging of depressive disorders would also clearly differentiate early-attenuated forms from first major episodes of illness (both typically occurring in adolescence or early adult years) and later recurrent, persistent or chronic forms.

Abbreviations

DSM: Diagnostic and Statistical Manual of Mental Disorders; ICD: International Classification of Diseases.

Competing interests

IBH was a director of headspace: the national youth mental health foundation until January 2012. He is the executive director of the Brain and Mind Research Institute (BMRI), which operates two early-intervention youth services under contract to headspace. He is a member of the new Australian National Mental Health commission and was previously the CEO of beyondblue: the national depression initiative. He has led a range of community-based and pharmaceutical industry-supported depression awareness and education and training programs. He has led depression and other mental health research projects that have been supported by a variety of pharmaceutical partners. Current investigator-initiated studies are supported by Servier and Pfizer. He has received honoraria for his contributions to professional educational seminars related to depression, youth mental health and circadian-rhythms research. DFH has received honoraria for educational seminars from Janssen-Cilag. EMS is the (unpaid) Clinical Director of Headspace Services at the BMRI, the (unpaid) Coordinator of the Youth Mental Health Research Program at the BMRI, and Deputy Director of St Vincent's Private Hospital Young Adult Mental Health Unit. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. PDM is director of headspace and also of Headstrong (Irish National YMH Foundation) and he holds Investigator Initiated Research Grant Support from Janssen Cilag, Eli Lilly, BMS and Astra Zeneca. PDM also has consultancy and advisory roles with Janssen Cilag, Eli Lilly, BMS, AZ Roche and Pfizer.

Authors' contributions

All authors discussed the evidence and contributed to the writing of this manuscript, primarily through a significant discourse undertaken over the past five years. All authors read and approved the final manuscript.

Acknowledgements

IBH, DFH and AJG are supported by an NHMRC Australia Fellowship awarded to IBH (464914). SLN is funded by an NHMRC Clinical Research Fellowship (402864). This work was further supported by NHMRC Program Grant (566529).

Author details

¹Clinical Research Unit, Brain & Mind Research Institute, University of Sydney, 100 Mallett Street, Camperdown 2050, Australia. ²Academic Psychiatry, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. ³FondaMental Foundation, Fondation de Coopération Scientifique Hôpital A. Chenevier, 40 Rue de Mesly, Creteil F-94000, France. ⁴INSERM, U 955, IMRB, Psychiatry Genetic, Creteil F-94000, France. ⁵School of Medicine, The University of Notre Dame, 160 Oxford Street, Darlinghurst, Sydney 2010, Australia. ⁶Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville 3052, Australia. ⁷Orygen Youth Health Research Centre, Department of Psychiatry, University of Melbourne, 35 Poplar Road, Parkville 3052, Australia.

Received: 25 July 2012 Accepted: 18 December 2012

Published: 14 May 2013

References

1. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jenum P,

- Jordanova A, Jonsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm JS: **Cost of disorders of the brain in Europe 2010.** *Eur Neuropsychopharmacol* 2011, **21**:718–779.
2. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo M-M, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ, Anderson W, Dhansay MA, Ewart W, Phillips A, et al: **Grand challenges in global mental health.** *Nature* 2011, **475**:27–30.
3. Hickie IB, Groom GL, McGorry PD, Davenport TA, Luscombe GM: **Australian mental health reform: time for real outcomes.** *Med J Aust* 2005, **182**:401–406.
4. Mental Health Council of Australia: *Not For Service: Experiences of Injustice and Despair in Mental Health Care in Australia.* Canberra: Mental Health Council of Australia; 2005.
5. Insel TR, Sahakian BJ: **Drug research: a plan for mental illness.** *Nature* 2012, **483**:269–269.
6. Hyman SE: **A glimmer of light for neuropsychiatric disorders.** *Nature* 2008, **455**:890–893.
7. Amara SG, Grillner S, Insel T, Nutt D, Tsumoto T: **Neuroscience in recession?** *Nat Rev Neurosci* 2011, **12**:297–302.
8. Insel TR: **Rethinking schizophrenia.** *Nature* 2010, **468**:187–193.
9. Wang PS, Insel TR: **NIMH-Funded Pragmatic Trials: moving on.** *Neuropsychopharmacology* 2010, **35**:2489–2490.
10. Morris SE, Insel TR: **Reconceptualizing schizophrenia.** *Schizophr Res* 2011, **127**:1–2.
11. *Diagnosing the D.S.M.* [http://www.nytimes.com/2012/05/12/opinion/break-up-the-psychiatric-monopoly.html]
12. *Psychiatry's bible, the DSM, is doing more harm than good.* [http://www.washingtonpost.com/opinions/psychiatrys-bible-the-dsm-is-doing-more-harm-than-good/2012/04/27/gJQAqy0WIT_story.html]
13. The Lancet: **Psychiatry's identity crisis.** *Lancet* 2012, **379**:1274.
14. American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders.* 4th edition. Washington DC: American Psychiatric Association; 2000. Text Revision.
15. World Health Organization: *ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines.* Geneva: World Health Organization; 1992.
16. Hyman SE: **The diagnosis of mental disorders: the problem of reification.** *Annu Rev Clin Psychol* 2010, **6**:155–179.
17. Hyman SE: **Can neuroscience be integrated into the DSM-V?** *Nat Rev Neurosci* 2007, **8**:725–732.
18. Wray NR, Pergadia ML, Blackwood DHR, Penninx BWJH, Gordon SD, Nyholt DR, Ripke S, MacIntyre DJ, McGhee KA, Maclean AW, Smit JH, Hottenga JJ, Willemsen G, Middeldorp CM, de Geus EJC, Lewis CM, McGuffin P, Hickie IB, van den Oord EJC, Liu JZ, Macgregor S, McEvoy BP, Byrne EM, Medland SE, Statham DJ, Henders AK, Heath AC, Montgomery GW, Martin NG, Boomsma DI, et al: **Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned.** *Mol Psychiatry* 2010, **17**:36–48.
19. *DSM-5: The Future of Psychiatric Diagnosis.* [http://www.dsm5.org/Pages/Default.aspx]
20. Buckholtz JW, Meyer-Lindenberg A: **Psychopathology and the human connectome: toward a transdiagnostic model of risk for mental illness.** *Neuron* 2012, **74**:990–1004.
21. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ: **Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions.** *Aust N Z J Psychiatry* 2006, **40**:616–622.
22. Hickie IB, Scott EM, Hermens DF, Naismith SL, Guastella AJ, Kaur M, Sidis A, Whitwell B, Glozier N, Pantelis C, Wood SJ, McGorry PD: **Applying a clinical staging framework in young people who present with admixtures of anxious, depressive or psychotic symptoms.** *Early Interv Psychiatry* 2013, **7**:31–43.
23. Nesse RM, Stein DJ: **Towards a genuinely medical model for psychiatric nosology.** *BMC Med* 2012, **10**:5.
24. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P: **Research domain criteria (RDoC): toward a new classification framework for research on mental disorders.** *Am J Psychiatry* 2010, **167**:748–751.
25. McGorry PD: **Risk syndromes, clinical staging and DSM V: new diagnostic infrastructure for early intervention in psychiatry.** *Schizophr Res* 2010, **120**:49–53.
26. White PD, Rickards H, Zeman AZJ: **Time to end the distinction between mental and neurological illnesses.** *BMJ* 2012, **344**:e3454.

27. McGorry PD: **The recognition and optimal management of early psychosis: applying the concept of staging in the treatment of psychosis.** In *Evolving Psychosis*. Edited by Johannessen JO, Martinvale BV, Cullberg J. New York: Routledge/Taylor & Francis Group; 2006.
28. Scott J, Hickie IB, McGorry P: **Pre-emptive psychiatric treatments: pipe dream or a realistic outcome of clinical staging models?** *Neuropsychiatry* 2012, **2**:263–266.
29. Merikangas KR, He J-P, Burstein M, Swanson SA, Avenevoli S, Cui L, Benjet C, Georgiades K, Swendsen J: **Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication Adolescent Supplement (NCS-A).** *J Am Acad Child Adolesc Psychiatry* 2010, **49**:980–989.
30. Paus T, Keshavan M, Giedd JN: **Why do many psychiatric disorders emerge during adolescence?** *Nat Rev Neurosci* 2008, **9**:947–957.
31. Hafner H, An Der Heiden W, Maurer K: **Evidence for separate diseases? Stages of one disease or different combinations of symptom dimensions?** *Eur Arch Psychiatry Clin Neurosci* 2008, **258** Suppl 2:85–96.
32. Gore FM, Bloem PJN, Patton GC, Ferguson J, Joseph V, Coffey C, Sawyer SM, Mathers CD: **Global burden of disease in young people aged 10–24 years: a systematic analysis.** *Lancet* 2011, **377**:2093–2102.
33. McGorry PD, Yung AR, Bechdolf A, Amminger P: **Back to the future: predicting and reshaping the course of psychotic disorder.** *Arch Gen Psychiatry* 2008, **65**:25–27.
34. McGorry PD: **Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry.** *Am J Psychiatry* 2007, **164**:859–860.
35. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM: **Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study.** *Lancet* 2009, **373**:234–239.
36. Sullivan PF, Daly MJ, O'Donovan M: **Genetic architectures of psychiatric disorders: the emerging picture and its implications.** *Nat Rev Genet* 2012, **13**:537–551.
37. Merikangas KR, Cui L, Kattan G, Carlson GA, Youngstrom EA, Angst J: **Mania with and without depression in a community sample of U.S. adolescents.** *Arch Gen Psychiatry* 2012, **69**:943–951.
38. Merikangas KR, Herrell R, Swendsen J, Rossler W, Ajdacic-Gross V, Angst J: **Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study.** *Arch Gen Psychiatry* 2008, **65**:47–52.
39. Kelleher I, Keeley H, Corcoran P, Lynch F, Fitzpatrick C, Devlin N, Molloy C, Roddy S, Clarke MC, Harley M, Arseneault L, Wasserman C, Carli V, Sarchiapone M, Hoven C, Wasserman D, Cannon M: **Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies.** *Br J Psychiatry* 2012, **201**:26–32.
40. Murray GK, Jones PB: **Psychotic symptoms in young people without psychotic illness: mechanisms and meaning.** *Br J Psychiatry* 2012, **201**:4–6.
41. Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R: **Prior juvenile diagnoses in adults with mental disorder: Developmental follow-back of a prospective-longitudinal cohort.** *Arch Gen Psychiatry* 2003, **60**:709–717.
42. Van Os J, Jones P, Sham P, Bebbington P, Murray RM: **Risk factors for onset and persistence of psychosis.** *Soc Psychiatry Psychiatr Epidemiol* 1998, **33**:596–605.
43. Van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L: **A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder.** *Psychol Med* 2009, **39**:179–195.
44. Tjissen MJA, van Os J, Wittchen H-U, Lieb R, Beesdo K, Mengelers R, Wichers M: **Prediction of transition from common adolescent bipolar experiences to bipolar disorder: 10-year study.** *Br J Psychiatry* 2010, **196**:102–108.
45. Gregory AM, Caspi A, Eley TC, Moffitt TE, O'Connor TG, Poulton R: **Prospective longitudinal associations between persistent sleep problems in childhood and anxiety and depression disorders in adulthood.** *J Abnorm Child Psychol* 2005, **33**:157–163.
46. Shorter E: *Before Prozac: The Troubled History of Mood Disorders in Psychiatry.* New York: Oxford University Press; 2009.
47. Horowitz AV, Wakefield JC: *The Loss of Sadness: How Psychiatry Transformed Normal Sorrow into Depressive Disorder.* New York: Oxford University Press; 2007.
48. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL: **Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.** *Lancet* 2006, **367**:1747–1757.
49. Beddington J, Cooper CL, Field J, Goswami U, Huppert FA, Jenkins R, Jones HS, Kirkwood TBL, Sahakian BJ, Thomas SM: **The mental wealth of nations.** *Nature* 2008, **455**:1057–1060.
50. Insel TR: **The arrival of preemptive psychiatry.** *Early Interv Psychiatry* 2007, **1**:5–6.
51. McGorry P: **Early intervention in psychiatry: the next developmental stage.** *Early Interv Psychiatry* 2012, **6**:1–2.
52. Hamilton BA, Naismith SL, Scott EM, Purcell S, Hickie IB: **Disability is already pronounced in young people with early stages of affective disorders: data from an early intervention service.** *J Affect Disord* 2011, **131**:84–91.
53. Scott EM, Hermens DF, Glozier N, Naismith SL, Guastella AJ, Hickie IB: **Targeted primary care-based mental health services for young Australians.** *Med J Aust* 2012, **196**:136–140.
54. Scott E, Naismith SL, Whitwell BG, Hamilton B, Chudleigh C, Hickie IB: **Delivering youth-specific mental health services: the advantages of a collaborative, multi-disciplinary system.** *Australas Psychiatry* 2009, **17**:189–194.
55. McGorry PD, Tanti C, Stokes R, Hickie IB, Carnell K, Littlefield LK, Moran J: **Headspace: Australia's National Youth Mental Health Foundation - where young minds come first.** *Med J Aust* 2007, **187**:S68.
56. McGorry PD, Killackey E, Yung AR: **Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages.** *Med J Aust* 2007, **187**:S8.
57. McGorry PD, Yung AR, Phillips LJ: **The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder.** *Schizophr Bull* 2003, **29**:771–790.
58. Naismith SL, Hermens DF, Ip TK, Bolitho S, Scott EM, Rogers NL, Hickie IB: **Circadian profiles in young people during the early stages of affective disorder.** *Transl Psychiatry* 2012, **2**:e123.
59. Lagopoulos J, Hermens D, Naismith S, Scott E, Hickie I: **Frontal lobe changes occur early in the course of affective disorders in young people.** *BMC Psychiatry* 2012, **12**:4.
60. Robillard R, Naismith SL, Rogers NL, Ip TK, Hermens DF, Scott EM, Hickie IB: **Delayed sleep phase in young people with unipolar or bipolar affective disorders.** *J Affect Disord* 2013, **145**:260–263.
61. Scott EM, Hermens DF, Naismith SL, Guastella AJ, De Regt T, White D, Lagopoulos J, Hickie IB: **Distinguishing young people with emerging bipolar disorders from those with unipolar depression.** *J Affective Dis* 2013, **144**:208–215.
62. Andrews G, Brughra T, Thase ME, Duffy FF, Rucci P, Slade T: **Dimensionality and the category of major depressive episode.** *Int J Methods Psychiatr Res* 2007, **16** Suppl 1:S41–S51.
63. Parker G, Hadzi-Pavlovic D, Brodaty H, Boyce P, Mitchell P, Wilhelm K, Hickie I, Eysers K: **Psychomotor disturbance in depression: defining the constructs.** *J Affect Disord* 1993, **27**:255–265.
64. Hickie I, Parsonage B, Parker G: **Prediction of response to electroconvulsive therapy. Preliminary validation of a sign-based typology of depression.** *Br J Psychiatry* 1990, **157**:65–71.
65. Parker G, Hadzi-Pavlovic D, Wilhelm K, Hickie I, Brodaty H, Boyce P, Mitchell P, Eysers K: **Defining melancholia: properties of a refined sign-based measure.** *Br J Psychiatry* 1994, **164**:316–326.
66. Hickie IB, Luscombe GM, Davenport TA, Burns JM, Highet NJ: **Perspectives of young people on depression: awareness, experiences, attitudes and treatment preferences.** *Early Interv Psychiatry* 2007, **1**:333–339.
67. Hickie I, Koschera A, Hadzi-Pavlovic D, Bennett B, Lloyd A: **The temporal stability and co-morbidity of prolonged fatigue: a longitudinal study in primary care.** *Psychol Med* 1999, **29**:855–861.
68. Koschera A, Hickie I, Hadzi-Pavlovic D, Wilson A, Lloyd A: **Prolonged fatigue, anxiety and depression: exploring relationships in a primary care sample.** *Aust N Z J Psychiatry* 1999, **33**:545–552.
69. Hickie IB, Koschera A, Davenport TA, Naismith SL, Scott EM: **Comorbidity of common mental disorders and alcohol or other substance misuse in Australian general practice.** *Med J Aust* 2001, **175** Suppl:S31–S36.
70. Carroll BJ: **Informed use of the dexamethasone suppression test.** *J Clin Psychiatry* 1986, **47**:10–12.
71. Naismith SL, Rogers NL, Lewis SJG, Terpening Z, Ip T, Diamond K, Norrie L, Hickie IB: **Sleep disturbance relates to neuropsychological functioning in late-life depression.** *J Affect Disord* 2011, **132**:139–145.
72. Hermens DF, Redoblado Hodge MA, Naismith SL, Kaur M, Scott E, Hickie IB: **Neuropsychological clustering highlights cognitive differences in young people presenting with depressive symptoms.** *J Int Neuropsychol Soc* 2011, **17**:267–276.

73. Hermens DF, Naismith SL, Redoblado Hodge MA, Scott EM, Hickie IB: **Impaired verbal memory in young adults with unipolar and bipolar depression.** *Early Interv Psychiatry* 2010, **4**:227–233.
74. Hickie IB, Naismith SL, Ward PB, Little CL, Pearson M, Scott EM, Mitchell P, Wilhelm K, Parker G: **Psychomotor slowing in older patients with major depression: relationships with blood flow in the caudate nucleus and white matter lesions.** *Psychiatry Res* 2007, **155**:211–220.
75. Naismith SL, Hickie IB, Turner K, Little CL, Winter V, Ward PB, Wilhelm K, Mitchell P, Parker G: **Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors.** *J Clin Exp Neuropsychol* 2003, **25**:866–877.
76. Hatton SN, Lagopoulos J, Hermens DF, Naismith SL, Bennett MR, Hickie IB: **Correlating anterior insula gray matter volume changes in young people with clinical and neurocognitive outcomes: an MRI study.** *BMC Psychiatry* 2012, **12**:45.
77. Naismith SL, Lagopoulos J, Ward PB, Davey CG, Little C, Hickie IB: **Fronto-striatal correlates of impaired implicit sequence learning in major depression: an fMRI study.** *J Affect Disord* 2010, **125**:256–261.
78. Hickie I, Naismith S, Ward PB, Turner K, Scott E, Mitchell P, Wilhelm K, Parker G: **Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression.** *Br J Psychiatry* 2005, **186**:197–202.
79. Naismith S, Hickie I, Ward PB, Turner K, Scott E, Little C, Mitchell P, Wilhelm K, Parker G: **Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression.** *Am J Psychiatry* 2002, **159**:2096–2098.
80. Hickie I, Ward P, Scott E, Haindl W, Walker B, Dixon J, Turner K: **Neo-striatal rCBF correlates of psychomotor slowing in patients with major depression.** *Psychiatry Res* 1999, **92**:75–81.
81. Hickie I, Scott E, Wilhelm K, Brodaty H: **Subcortical hyperintensities on magnetic resonance imaging in patients with severe depression—a longitudinal evaluation.** *Biol Psychiatry* 1997, **42**:367–374.
82. Hickie I, Scott E, Mitchell P, Wilhelm K, Austin MP, Bennett B: **Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression.** *Biol Psychiatry* 1995, **37**:151–160.
83. Naismith SL, Norrie LM, Mowszowski L, Hickie IB: **The neurobiology of depression in later-life: clinical, neuropsychological, neuroimaging and pathophysiological features.** *Prog Neurobiol* 2012, **98**:99–143.
84. Hickie IB, Naismith SL, Norrie LM, Scott EM: **Managing depression across the life cycle: new strategies for clinicians and their patients.** *Intern Med J* 2009, **39**:720–727.
85. Allen NB, Hetrick SE, Simmons JG, Hickie IB: **Early intervention for depressive disorders in young people: the opportunity and the (lack of) evidence.** *Med J Aust* 2007, **187**:S15.
86. Hickie I, Scott E, Naismith S, Ward PB, Turner K, Parker G, Mitchell P, Wilhelm K: **Late-onset depression: genetic, vascular and clinical contributions.** *Psychol Med* 2001, **31**:1403–1412.
87. Gillespie NA, Kirk KM, Evans DM, Heath AC, Hickie IB, Martin NG: **Do the genetic or environmental determinants of anxiety and depression change with age? A longitudinal study of Australian twins.** *Twin Res* 2004, **7**:39–53.
88. McGorry PD, Purcell R, Hickie IB, Yung AR, Pantelis C, Jackson HJ: **Clinical staging: a heuristic model for psychiatry and youth mental health.** *Med J Aust* 2007, **187**:S40.
89. Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, Reeves WC, Lloyd A, Dubbo Infection Outcomes Study Group: **Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study.** *BMJ* 2006, **333**:575.
90. Avenevoli S, Merikangas KR: **Implications of high-risk family studies for prevention of depression.** *Am J Prevent Med* 2006, **31**:126–135.
91. Merikangas KR, Lieb R, Wittchen HU, Avenevoli S: **Family and high-risk studies of social anxiety disorder.** *Acta Psychiatr Scand Suppl* 2003, **417**:28–37.
92. Preisig M, Fenton BT, Stevens DE, Merikangas KR: **Familial relationship between mood disorders and alcoholism.** *Compr Psychiatry* 2001, **42**:87–95.
93. Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA, Fenton B, Zhang H, O'Malley SS, Rounsaville BJ: **Familial transmission of substance use disorders.** *Arch Gen Psychiatry* 1998, **55**:973–979.
94. Milne BJ, Caspi A, Harrington H, Poulton R, Rutter M, Moffitt TE: **Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependence.** *Arch Gen Psychiatry* 2009, **66**:738–747.
95. Angst J, Azorin J-M, Bowden CL, Perugi G, Vieta E, Gamma A, Young AH, for the BSG: **Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: The BRIDGE study.** *Arch Gen Psychiatry* 2011, **68**:791–799.
96. Boyce P, Hickie I, Parker G: **Parents, partners or personality? Risk factors for post-natal depression.** *J Affect Disord* 1991, **21**:245–255.
97. Hickie I, Parker G: **The impact of an uncaring partner on improvement in non-melancholic depression.** *J Affect Disord* 1992, **25**:147–160.
98. Hickie I, Parker G, Wilhelm K, Tennant C: **Perceived interpersonal risk factors of non-endogenous depression.** *Psychol Med* 1991, **21**:399–412.
99. Hansell NK, Wright MJ, Medland SE, Davenport TA, Wray NR, Martin NG, Hickie IB: **Genetic co-morbidity between neuroticism, anxiety/depression and somatic distress in a population sample of adolescent and young adult twins.** *Psychol Med* 2012, **42**:1249–1260.
100. Chiang M-C, McMahon KL, de Zubicaray GI, Martin NG, Hickie I, Toga AW, Wright MJ, Thompson PM: **Genetics of white matter development: a DTI study of 705 twins and their siblings aged 12 to 29.** *Neuroimage* 2011, **54**:2308–2317.
101. Merikangas KR, Lamers F: **The 'true' prevalence of bipolar II disorder.** *Curr Opin Psychiatry* 2012, **25**:19–23.
102. Hetrick SE, Parker AG, Hickie IB, Purcell R, Yung AR, McGorry PD: **Early identification and intervention in depressive disorders: towards a clinical staging model.** *Psychother Psychosom* 2008, **77**:263–270.
103. Dubicka B, Elvins R, Roberts C, Chick G, Wilkinson P, Goodyer IM: **Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis.** *Br J Psychiatry* 2010, **197**:433–440.
104. Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, Iyengar S, Shamseddeen W, Ritz L, Birmaher B, Ryan N, Kennard B, Mayes T, DeBar L, McCracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M, Brent D: **Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.** *J Am Acad Child Adolesc Psychiatry* 2009, **48**:330–339.
105. Curry J, Rohde P, Simons A, Silva S, Vitiello B, Kratochvil C, Reinecke M, Feeny N, Wells K, Pathak S, Weller E, Rosenberg D, Kennard B, Robins M, Ginsburg G, March J: **Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).** *J Am Acad Child Adolesc Psychiatry* 2006, **45**:1427–1439.
106. Hermens DF, Lagopoulos J, Naismith SL, Tobias-Webb J, Hickie IB: **Distinct neurometabolic profiles are evident in the anterior cingulate of young people with major psychiatric disorders.** *Transl Psychiatry* 2012, **2**:e110.
107. Libby AM, Orton HD, Stover SK, Riggs PD: **What came first, major depression or substance use disorder? Clinical characteristics and substance use comparing teens in a treatment cohort.** *Addict Behav* 2005, **30**:1649–1662.
108. Hermens DF, Lagopoulos J, Tobias-Webb J, De Regt T, Dore G, Juckes L, Latt N, Hickie IB: **Pathways to alcohol-induced brain impairment in young people: a review.** *Cortex* 2013, **49**:3–17.
109. Conway KP, Compton W, Stinson FS, Grant BF: **Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.** *J Clin Psychiatry* 2006, **67**:247–257.
110. Compton WM, Thomas YF, Conway KP, Colliver JD: **Developments in the epidemiology of drug use and drug use disorders.** *Am J Psychiatry* 2005, **162**:1494–1502.
111. Vieta E, Sanchez-Moreno J, Lahuerta J, Zaragoza S, Group E: **Subsyndromal depressive symptoms in patients with bipolar and unipolar disorder during clinical remission.** *J Affect Disord* 2008, **107**:169–174.
112. Wilcox HC, Anthony JC: **Child and adolescent clinical features as forerunners of adult-onset major depressive disorder: retrospective evidence from an epidemiological sample.** *J Affect Disord* 2004, **82**:9–20.
113. Dunlop BW, Binder EB, Cubells JF, Goodman MG, Kelley ME, Kinkead B, Kutner M, Nemeroff CB, Newport DJ, Owens MJ, Pace TW, Ritchie JC, Aponte Rivera V, Westen D, Craighead WE, Mayberg HS: **Predictors of remission in depression to individual and combined treatments (PREDiCT): study protocol for a randomized controlled trial.** *Trials* 2012, **13**:106.
114. Hickie I, Naismith S, Ward PB, Scott E, Mitchell P, Wilhelm K, Parker G: **Vascular risk and low serum B12 predict white matter lesions in patients with major depression.** *J Affect Disord* 2005, **85**:327–332.
115. Plante GE: **Depression and cardiovascular disease: a reciprocal relationship.** *Metabolism* 2005, **54**:45–48.
116. Camus V, Kraehenbuhl H, Preisig M, Bula CJ, Waeber G, Camus V, Kraehenbuhl H, Preisig M, Bula CJ, Waeber G: **Geriatric depression and vascular diseases: what are the links? J Affect Disord 2004, **81**:1–16.**

117. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K, Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K: **Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study.** *Arch Gen Psychiatry* 2006, **63**:273–279.
118. Bruce DG, Casey G, Davis WA, Starkstein SE, Clarnette RC, Foster JK, Ives FJ, Almeida OP, Davis TM, Bruce DG, Casey G, Davis WA, Starkstein SE, Clarnette RC, Foster JK, Ives FJ, Almeida OP, Davis TME: **Vascular depression in older people with diabetes.** *Diabetologia* 2006, **49**:2828–2836.
119. Almeida OP, Flicker L, Norman P, Hankey GJ, Vasikaran S, van Bockxmeer FM, Jamrozik K: **Association of cardiovascular risk factors and disease with depression in later life.** *Am J Geriatr Psychiatry* 2007, **15**:506–513.
120. Meyers BS, Klimstra SA, Gabriele M, Hamilton M, Kakuma T, Tirumalasetti F, Alexopoulos GS, Meyers BS, Klimstra SA, Gabriele M, Hamilton M, Kakuma T, Tirumalasetti F, Alexopoulos GS: **Continuation treatment of delusional depression in older adults.** *Am J Geriatr Psychiatry* 2001, **9**:415–422.
121. Monteleone P, Martiadis V, Maj M: **Circadian rhythms and treatment implications in depression.** *Prog Neuropsychopharmacol Biol Psychiatry* 2011, **35**:1569–1574.
122. Hickie IB, Rogers NL: **Novel melatonin-based therapies: potential advances in the treatment of major depression.** *Lancet* 2011, **378**:621–631.
123. Gorwood P: **Restoring circadian rhythms: a new way to successfully manage depression.** *J Psychopharmacol* 2010, **24**:15–19.
124. Monteleone P, Maj M: **The circadian basis of mood disorders: recent developments and treatment implications.** *Eur Neuropsychopharmacol* 2008, **18**:701–711.
125. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y-H, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M: **National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants.** *Lancet* 2011, **378**:31–40.
126. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M: **Prediabetes: a high-risk state for diabetes development.** *Lancet* 2012, **379**:2279–2290.
127. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE: **Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.** *Lancet* 2012, **379**:2243–2251.
128. The Lancet: **Prediabetes and the potential to prevent diabetes.** *Lancet* 2012, **379**:2213.
129. Hickie IB, Fogarty AS, Davenport TA, Luscombe GM, Burns J: **Responding to experiences of young people with common mental health problems attending Australian general practice.** *Med J Aust* 2007, **187**:547.
130. Hickie IB: **Youth mental health: we know where we are and we can now say where we need to go next.** *Early Interv Psychiatry* 2011, **5**:63–69.
131. Phillips J, Frances A, Cerullo M, Chardavoyne J, Decker H, First M, Ghaemi N, Greenberg G, Hinderliter A, Kinghorn W, LoBello S, Martin E, Mishara A, Paris J, Pierre J, Pies R, Pincus H, Porter D, Pouncey C, Schwartz M, Szasz T, Wakefield J, Waterman GS, Whooley O, Zachar P: **The six most essential questions in psychiatric diagnosis: a pluralogue part 1: conceptual and definitional issues in psychiatric diagnosis.** *Philos Ethics Hum Med* 2012, **7**:3.
132. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD: **Five-hundred life-saving interventions and their cost-effectiveness.** *Risk Anal* 1995, **15**:369–390.
133. Smith SC Jr, Collins A, Ferrari R, Holmes DR Jr, Logstrup S, McGhie DV, Ralston J, Sacco RL, Stam H, Taubert K, Wood DA, Zoghbi WA: **Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke).** *Circulation* 2012, **60**:2343–2348.
134. Banati RB, Hickie IB: **Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders.** *Med J Aust* 2009, **190**:S26–S32.
135. Hickie IB, McGorry PD: **Characterising novel pathways to schizophrenia.** *Med J Aust* 2009, **190**:S5–S6.
136. Kaur M, Battisti RA, Lagopoulos J, Ward PB, Hickie IB, Hermens DF: **Neurophysiological biomarkers support bipolar-spectrum within psychosis cluster.** *J Psychiatry Neurosci* 2012, **37**:313–321.
137. Andrews G, Titov N: **Depression is very disabling.** *Lancet* 2007, **370**:808–809.
138. Archie S, Zangeneh Kazemi A, Akhtar-Danesh N: **Concurrent binge drinking and depression among Canadian youth: prevalence, patterns, and suicidality.** *Alcohol* 2012, **46**:165–172.
139. Boden JM, Fergusson DM: **Alcohol and depression.** *Addiction* 2011, **106**:906–914.
140. Bond L, Toumbourou JW, Thomas L, Catalano RF, Patton G: **Individual, family, school, and community risk and protective factors for depressive symptoms in adolescents: a comparison of risk profiles for substance use and depressive symptoms.** *Prev Sci* 2005, **6**:73–88.
141. Bunker SJ, Colquhoun DM, Esler MD, Hickie IB, Hunt D, Jelinek VM, Oldenburg BF, Peach HG, Ruth D, Tennant CC, Tonkin AM: **“Stress” and coronary heart disease: psychosocial risk factors.** *Med J Aust* 2003, **178**:272–276.
142. Goldberg D, Fawcett J: **The importance of anxiety in both major depression and bipolar disorder.** *Dep Anxiety* 2012, **29**:471–478.
143. Simms LJ, Prisciandaro JJ, Krueger RF, Goldberg DP: **The structure of depression, anxiety and somatic symptoms in primary care.** *Psychol Med* 2012, **42**:15–28.
144. Goldberg DP, Andrews G, Hobbs MJ: **Where should bipolar disorder appear in the meta-structure?** *Psychol Med* 2009, **39**:2071–2081.
145. Andrews G, Goldberg DP, Krueger RF, Carpenter WT, Hyman SE, Sachdev P, Pine DS: **Exploring the feasibility of a meta-structure for DSM-V and ICD-11: could it improve utility and validity?** *Psychol Med* 2009, **39**:1993–2000.
146. Cuthbert BN, Insel TR: **Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria Project.** *Schizophr Bull* 2010, **36**:1061–1062.
147. Pesa N, Hermens D, Battisti R, Kaur M, Hickie I, Solowij N: **Delayed preattentive functioning in early psychosis patients with cannabis use.** *Psychopharmacology (Berl)* 2012, **222**:507–518.
148. Chitty KM, Kaur M, Lagopoulos J, Hickie IB, Hermens DF: **Alcohol use and mismatch negativity in young subjects with psychotic disorder.** *Neuroreport* 2011, **17**:918–922.
149. The APA Task Force on Laboratory Tests in Psychiatry: **The dexamethasone suppression test: an overview of its current status in psychiatry.** *Am J Psychiatry* 1987, **144**:1253–1262.
150. Kaur M, Battisti RA, Ward PB, Ahmed A, Hickie IB, Hermens DF: **MMN/P3a deficits in first episode psychosis: comparing schizophrenia-spectrum and affective-spectrum subgroups.** *Schizophr Res* 2011, **130**:203–209.
151. Hermens DF, Ward PB, Hodge MAR, Kaur M, Naismith SL, Hickie IB: **Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations.** *Prog Neuropsychopharmacol Biol Psychiatry* 2010, **34**:822–829.
152. Caspi A, Moffitt TE: **Gene-environment interactions in psychiatry: joining forces with neuroscience.** *Nat Rev Neurosci* 2006, **7**:583–590.
153. Kuepper R, Myin-Germeys I, Konings M, van Winkel R, van Os J, Henquet C: **Exploring the causal relationship between cannabis and schizophrenia: what is the role of genes and environment?** *Eur Psychiatry* 2009, **24**:S31–S31.
154. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM: **Gene-environment interplay between cannabis and psychosis.** *Schizophr Bull* 2008, **34**:1111–1121.
155. Illi J, Miaskowski C, Cooper B, Levine JD, Dunn L, West C, Dodd M, Dhruva A, Paul SM, Baggott C, Cataldo J, Langford D, Schmidt B, Auouizerat BE: **Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression.** *Cytokine* 2012, **58**:437–447.
156. Bennett B, Goldstein D, Friedlander M, Hickie I, Lloyd A: **The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study.** *J Pain Symptom Manage* 2007, **34**:126–135.
157. Scott J: **Bipolar disorder: from early identification to personalized treatment.** *Early Interv Psychiatry* 2011, **5**:89–90.
158. Scott JAN, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, Abbott R, Hayhurst H: **Cognitive-behavioural therapy for severe and recurrent bipolar disorders.** *Br J Psychiatry* 2006, **188**:313–320.
159. McGorry PD: **Is early intervention in the major psychiatric disorders justified? Yes.** *BMJ* 2008, **337**:a695.
160. Hickie I: **Is depression overdiagnosed? No.** *BMJ* 2007, **335**:329.
161. Parker G: **Is depression overdiagnosed? Yes.** *BMJ* 2007, **335**:328.
162. McGorry PD, Yung AR, Pantelis C, Hickie IB: **A clinical trials agenda for testing interventions in earlier stages of psychotic disorders.** *Med J Aust* 2009, **190**:S33–S36.
163. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, Riecher-Rossler A, Klosterkotter J, Ruhrmann S, Schultze-Lutter F, Nordentoft M, Hickie I, McGuire P, Berk M, Chen EYH, Keshavan MS, Yung AR: **Intervention in individuals at ultra-high risk for psychosis: a review and future directions.** *J Clin Psychiatry* 2009, **70**:1206–1212.

164. Hickie IB, Banati RB, Stewart CH, Lloyd AR: **Are common childhood or adolescent infections risk factors for schizophrenia and other psychotic disorders?** *Med J Aust* 2009, **190**:S17–S21.
165. Kantomaa MT, Tammelin TH, Ebeling HE, Taanila AM: **Emotional and behavioral problems in relation to physical activity in youth.** *Med Sci Sports Exerc* 2008, **40**:1749–1756.
166. Ichiki M, Kunugi H, Takei N, Murray RM, Baba H, Arai H, Oshima I, Okagami K, Sato T, Hirose T, Nanko S: **Intra-uterine physical growth in schizophrenia: evidence confirming excess of premature birth.** *Psychol Med* 2000, **30**:597–604.
167. Licinio J, Wong ML: **Advances in depression research: 2011.** *Mol Psychiatry* 2011, **16**:686–687.
168. Glozier N, Martiniuk A, Patton G, Ivers R, Li Q, Hickie I, Senserrick T, Woodward M, Norton R, Stevenson M: **Short sleep duration in prevalent and persistent psychological distress in young adults: the DRIVE study.** *Sleep* 2010, **33**:1139–1145.
169. Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S: **Agomelatine in the treatment of seasonal affective disorder.** *Psychopharmacology (Berl)* 2007, **190**:575–579.
170. Schwarz PE, Reimann M, Li J, Bergmann A, Licinio J, Wong ML, Bornstein SR: **The metabolic syndrome - a global challenge for prevention.** *Horm Metab Res* 2007, **39**:777–780.
171. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Bayle FJ: **Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.** *J Clin Psychiatry* 2010, **71**:109–120.
172. Ehlers CL, Kupfer DJ, Frank E, Monk TH: **Biological rhythms and depression: the role of zeitgebers and zeitstorerers.** *Depression* 1993, **1**:285–293.
173. Terman M, Terman JS: **Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects.** *CNS Spectr* 2005, **10**:647–663. quiz 672.
174. Barbini B, Benedetti F, Colombo C, Dotoli D, Bernasconi A, Cigala-Fulgosi M, Florita M, Smeraldi E: **Dark therapy for mania: a pilot study.** *Bipolar Disord* 2005, **7**:98–101.
175. Quera Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, Lofaso F, Guilleminault C: **Major depressive disorder, sleep EEG and agomelatine: an open-label study.** *Int J Neuropsychopharmacol* 2007, **10**:691–696.
176. Mansour HA, Monk TH, Nimgaonkar VL: **Circadian genes and bipolar disorder.** *Ann Med* 2005, **37**:196–205.
177. McCarthy MJ, Nievergelt CM, Kelsoe JR, Welsh DK: **A survey of genomic studies supports association of circadian clock genes with bipolar disorder spectrum illnesses and lithium response.** *PLoS One* 2012, **7**:e32091.
178. Mukherjee S, Coque L, Cao JL, Kumar J, Chakravarty S, Asaithamby A, Graham A, Gordon E, Enwright JF 3rd, DiLeone RJ, Birnbaum SG, Cooper DC, McClung CA: **Knockdown of Clock in the ventral tegmental area through RNA interference results in a mixed state of mania and depression-like behavior.** *Biol Psychiatry* 2010, **68**:503–511.
179. Coque L, Mukherjee S, Cao JL, Spencer S, Marvin M, Falcon E, Sidor MM, Birnbaum SG, Graham A, Neve RL, Gordon E, Ozburn AR, Goldberg MS, Han MH, Cooper DC, McClung CA: **Specific role of VTA dopamine neuronal firing rates and morphology in the reversal of anxiety-related, but not depression-related behavior in the ClockDelta19 mouse model of mania.** *Neuropsychopharmacology* 2011, **36**:1478–1488.
180. Solberg LC, Horton TH, Turek FW: **Circadian rhythms and depression: effects of exercise in an animal model.** *Am J Physiol* 1999, **276**:R152–R161.
181. Kaladchibachi SA, Doble B, Anthopoulos N, Woodgett JR, Manoukian AS: **Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium.** *J Circ Rhythms* 2007, **5**:3.
182. Yagita K, Tamanini F, van Der Horst GT, Okamura H: **Molecular mechanisms of the biological clock in cultured fibroblasts.** *Science* 2001, **292**:278–281.
183. Yang S, Van Dongen HP, Wang K, Berrettini W, Bucan M: **Assessment of circadian function in fibroblasts of patients with bipolar disorder.** *Mol Psychiatry* 2009, **14**:143–155.
184. Ito N, Ito T, Kromminga A, Bettermann A, Takigawa M, Kees F, Straub RH, Paus R: **Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol.** *FASEB J* 2005, **19**:1332–1334.
185. Raul JS, Cirimele V, Ludes B, Kintz P: **Detection of physiological concentrations of cortisol and cortisone in human hair.** *Clin Biochem* 2004, **37**:1105–1111.
186. Licinio J: **Translational psychiatry: leading the transition from the cesspool of devastation to a place where the grass is really greener.** *Transl Psychiatry* 2011, **1**:e1.
187. Licinio J, Wong ML: **Pharmacogenomics of antidepressants: what is next?** *Mol Psychiatry* 2010, **15**:445–445.
188. Bornstein SR, Licinio J: **Improving the efficacy of translational medicine by optimally integrating health care, academia and industry.** *Nat Med* 2011, **17**:1567–1569.

doi:10.1186/1741-7015-11-125

Cite this article as: Hickie et al.: Clinical classification in mental health at the cross-roads: which direction next?. *BMC Medicine* 2013 **11**:127.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

